For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
40
views
13
references
 Top references
cited by
492
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,374
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

          Rury R Holman, M Angelyn Bethel, Robert J Mentz … (2017)
          The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
          Article 0 comments Cited 671 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

            Adrian Hernandez, Jennifer B Green, Salim Janmohamed … (2018)
            Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
            Article 0 comments Cited 568 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

              Adie Viljoen, Camilla Andreassen, Andrea Navarria … (2018)
              Despite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head trial compared semaglutide with dulaglutide in patients with inadequately controlled type 2 diabetes.
              Article 0 comments Cited 240 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: New England Journal of Medicine
                Abbreviated Title: N Engl J Med
                Publisher: Massachusetts Medical Society
                ISSN (Print): 0028-4793
                ISSN (Electronic): 1533-4406
                Publication date Created: June 11 2019
                Publication date (Electronic): June 11 2019
                Affiliations
                [1 ]From the Peter Munk Cardiac Centre, University Health Network, Department of Medicine and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto General Hospital Research Institute, and the Ted Rogers Centre for Heart Research, Toronto (M.H.), and the C-endo Diabetes and Endocrinology Clinic, Calgary, AB (S.D.P.) — all in Canada; Medical Clinic III, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, and the Paul Langerhans Institute Dresden of Helmholtz Zentrum...
                Article
                DOI: 10.1056/NEJMoa1901118
                PubMed ID: 31185157
                SO-VID: c1989795-e379-4394-b973-ce0f8d85f39b
                Copyright © © 2019
                License:

                http://www.nejmgroup.org/legal/terms-of-use.htm

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,374

                See all similar

                Cited by489

                See all cited by

                Most referenced authors1,340

                See all reference authors